ImmunoPrecise Antibodies Ltd. (HYFT) - Total Liabilities
Based on the latest financial reports, ImmunoPrecise Antibodies Ltd. (HYFT) has total liabilities worth $8.40 Million USD as of October 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ImmunoPrecise Antibodies Ltd. - Total Liabilities Trend (1997–2025)
This chart illustrates how ImmunoPrecise Antibodies Ltd.'s total liabilities have evolved over time, based on quarterly financial data. See HYFT working capital ratio to evaluate short-term liquidity relative to the company's equity base.
ImmunoPrecise Antibodies Ltd. Competitors by Total Liabilities
The table below lists competitors of ImmunoPrecise Antibodies Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Infas Holding AG
F:IFS
|
Germany | €59.22 Million |
|
Korea Cable T.V Chung-Buk System Co. Ltd.
KQ:066790
|
Korea | ₩3.21 Billion |
|
Astra Exploration Inc
V:ASTR
|
Canada | CA$189.01K |
|
Tirupati Forge Limited
NSE:TIRUPATIFL
|
India | Rs472.53 Million |
|
Redtone International Bhd
KLSE:0032
|
Malaysia | RM135.88 Million |
|
Osteonic Co. Ltd
KQ:226400
|
Korea | ₩32.25 Billion |
|
Hankook Furniture Co. Ltd
KQ:004590
|
Korea | ₩52.62 Billion |
|
Netbay Public Company Limited
BK:NETBAY
|
Thailand | ฿201.59 Million |
Liability Composition Analysis (1997–2025)
This chart breaks down ImmunoPrecise Antibodies Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ImmunoPrecise Antibodies Ltd. (HYFT) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ImmunoPrecise Antibodies Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ImmunoPrecise Antibodies Ltd. (1997–2025)
The table below shows the annual total liabilities of ImmunoPrecise Antibodies Ltd. from 1997 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-04-30 | $20.82 Million | -20.15% |
| 2024-04-30 | $26.07 Million | +30.27% |
| 2023-04-30 | $20.01 Million | +8.98% |
| 2022-04-30 | $18.36 Million | +82.98% |
| 2021-04-30 | $10.04 Million | -17.59% |
| 2020-04-30 | $12.18 Million | +18.49% |
| 2019-04-30 | $10.28 Million | -13.44% |
| 2018-04-30 | $11.87 Million | +1318.60% |
| 2017-04-30 | $836.91K | +77.26% |
| 2016-04-30 | $472.15K | +85.42% |
| 2015-04-30 | $254.64K | -16.10% |
| 2014-04-30 | $303.50K | +14.26% |
| 2013-04-30 | $265.63K | +24.65% |
| 2012-04-30 | $213.10K | +150.14% |
| 2011-04-30 | $85.19K | -15.21% |
| 2010-04-30 | $100.47K | -33.39% |
| 2009-04-30 | $150.84K | +302.67% |
| 2008-04-30 | $37.46K | -75.96% |
| 2007-04-30 | $155.85K | +12.43% |
| 2006-04-30 | $138.62K | +193.83% |
| 2005-04-30 | $47.18K | -5.49% |
| 2004-04-30 | $49.92K | +211.57% |
| 2003-04-30 | $16.02K | -91.47% |
| 2002-04-30 | $187.72K | -79.07% |
| 2001-04-30 | $896.75K | +8770.78% |
| 2000-04-30 | $10.11K | -71.75% |
| 1999-04-30 | $35.78K | -46.90% |
| 1998-04-30 | $67.39K | -73.05% |
| 1997-04-30 | $250.04K | -- |
About ImmunoPrecise Antibodies Ltd.
MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock ther… Read more